Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026437 | 0.87 | ALDH1A1 (0.83) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL14443021 | 0.84 | ALDH1A1 (0.68) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL1372147 | 0.82 | CYP1A2 (0.75) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL13804475 | 0.82 | ALDH1A1 (0.71) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL10076137 | 0.81 | ALDH1A1 (0.66) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL26814573 | 0.81 | MAPT (0.51) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL17207529 | 0.81 | CYP2D6 (0.79) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL1372144 | 0.80 | ALDH1A1 (0.73) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL3099181 | 0.80 | ALDH1A1 (0.73) | ALDH1A1NPSR1HTTMAPK1TSHR | |
| SCHEMBL4721495 | 0.80 | ALDH1A1 (0.67) | ALDH1A1NPSR1HTTMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | ALDH1A1 480/4885NPSR1 2153/4885HTT 3260/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | ALDH1A1 480/4885NPSR1 2153/4885HTT 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.